- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02191072
Efficacy and Safety of Omalizumab in Patients With Severe Acute Urticaria
July 14, 2014 updated by: National Taiwan University Hospital
Efficacy of omalizumab in chronic spontaneous urticaria had been demonstrated in phase II and phase III studies.
Clinical symptoms and signs had been significantly reduced with omalizumab as doses of 150 mg and 300 mg at 4-week intervals in patients with chronic spontaneous urticaria who remained symptomatic despite antihistamine treatment.
Omalizumab had an onset of effect within a week after initiation.
Thus, the investigators hypothesize that omalizumab will be effective in the treatment of severe acute urticaria as add on therapy with a fast onset of action.
Objective:To investigate the efficacy and safety of omalizumab in the treatment of severe acute urticaria Study design: This prospective, interventional, single-arm open label study will recruit patients with severe acute urticaria from emergency departments, hospitalized and outpatient departments.
The included patients will receive a single subcutaneous dose of 300mg omalizumab therapy.
The efficacy of omalizumab will be evaluated by physical examination and assessed by Urticaria Activity Score (UAS) at baseline, 1 hour, Day 1, Day3, Day 7, and 6 weeks after omalizumab therapy.
The frequency and severity of treatment-emergent adverse events will also be evaluated
Study Overview
Detailed Description
Acute urticaria is defined as hives that persist less than 6 weeks.
Some patients with acute urticaria may progressed and need urgent management at urgent care clinics and emergency rooms.
Nonsedating H1-antihistamines represent the mainstay and corticosteroids and various immunosuppressive therapies are being used in severely affected patients, or for those patients who experience a poor response to antihistamines.
However, even though already treated by antihistamines, the symptoms still last longer than 3 days in more than 34% of the patients.
Efficacy of omalizumab in chronic spontaneous urticaria had been demonstrated in phase II and phase III studies.
Clinical symptoms and signs had been significantly reduced with omalizumab as doses of 150 mg and 300 mg at 4-week intervals in patients with chronic spontaneous urticaria who remained symptomatic despite antihistamine treatment.
Omalizumab had an onset of effect within a week after initiation.
Thus, the investigators hypothesize that omalizumab will be effective in the treatment of severe acute urticaria as add on therapy with a fast onset of action.
Objective:To investigate the efficacy and safety of omalizumab in the treatment of severe acute urticaria Study design: This prospective, interventional, single-arm open label study will recruit patients with severe acute urticaria from emergency departments, hospitalized and outpatient departments.
The included patients will receive a single subcutaneous dose of 300mg omalizumab therapy.
The efficacy of omalizumab will be evaluated by physical examination and assessed by Urticaria Activity Score (UAS) at baseline, 1 hour, Day 1, Day3, Day 7, and 6 weeks after omalizumab therapy.
The frequency and severity of treatment-emergent adverse events will also be evaluated.
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hsien-Yi Chiu, MD
- Phone Number: 886-972654317
- Email: extra.owl0430@yahoo.com.tw
Study Contact Backup
- Name: Tsen-Fang Tasi, MD
- Phone Number: 886-2-23562141
- Email: tftsai@yahoo.com
Study Locations
-
-
-
Taipei, Taiwan, 100
- National Taiwan University Hospital
-
Contact:
- Tsai Tsen-Fang
- Phone Number: 886-972651561
- Email: tftsai@yahoo.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 20-75 years(2)Documented diagnosis of acute urticaria within 3 years
- Documented diagnosis of acute urticaria within 3 years
- Daily UAS at the beginning of study more than or equal to 4
- At time of enrollment, the symptoms of this episode had persisted longer than 3 days even under oral/intravenous antihistamines with or without oral corticosteroid therapy
Exclusion Criteria:
- Weight < 20 kg
- Continuous use of suspected drugs that may induce acute urticaria
- Pregnant woman
- Evidence of parasitic infection defined as having the following three items:Risk factors for parasitic disease (living in an endemic area, chronic gastrointestinal (GI) symptoms, travel within the last 6 months to an endemic area and/or chronic immunosuppression) AND An absolute eosinophil count more than twice the upper limit of normal AND Evidence of parasitic colonization or infection on stool evaluation for ova and parasites. Note that stool ova and parasite evaluation will only be conducted in patients with both risk factors and an eosinophil count more than twice the upper limit of normal.
- Atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or other skin disease associated with itch
- Treatment with omalizumab within 12 months before screening
- Treatment with any investigational agent within 30 days of screening
- IV immunoglobulin G (IVIG), or plasmapheresis within 30 days prior to Day -14
- Regular (daily/every other day) doxepin (oral) use within 6 weeks prior to Day -14
- Patients with current malignancy, history of malignancy, or currently under work-up for suspected malignancy except non-melanoma skin cancer that has been treated or excised and is considered resolved
- Hypersensitivity to omalizumab or any component of the formulation
- History of anaphylactic shock
- Presence of clinically significant cardiovascular, neurological, psychiatric, metabolic or other pathological conditions that could interfere with the interpretation of the study results and or compromise the safety of the patients
- Medical examination or laboratory findings that suggest the possibility of decompensation of co-existing conditions for the duration of the study. Any items that are cause for uncertainty must be reviewed with the Medical Monitor
- Inability to comply with study and follow-up procedures
- Evidence of current drug or alcohol abuse
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: omalizumab
omalizumab 300mg subcutaneously once
|
a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in daily Urticaria Activity Score
Time Frame: D0,1,2,3,4,5,6,7and 1 hour
|
Change in daily UAS from baseline to Day7 in the treatment period
|
D0,1,2,3,4,5,6,7and 1 hour
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of patient with daily UAS=0 at Day 1, Day 3
Time Frame: Day 1,3
|
Day 1,3
|
Change from baseline in itch severity score
Time Frame: Day 0,1,3
|
Day 0,1,3
|
Change from baseline in size of largest hive score
Time Frame: Day 0,1, 3
|
Day 0,1, 3
|
Proportion of patient could stop H1-antihistamine treatment
Time Frame: Day 0,3
|
Day 0,3
|
Proportion of angioedema-free days
Time Frame: Day 3,4,5,6,7
|
Day 3,4,5,6,7
|
The frequency and severity of treatment-emergent AEs and SAEs
Time Frame: 6 weeks follow-up period
|
6 weeks follow-up period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Tsai Tsen-Fang, Department of Dermatology, National Taiwan University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2014
Primary Completion (Anticipated)
May 1, 2016
Study Completion (Anticipated)
May 1, 2016
Study Registration Dates
First Submitted
July 9, 2014
First Submitted That Met QC Criteria
July 14, 2014
First Posted (Estimate)
July 15, 2014
Study Record Updates
Last Update Posted (Estimate)
July 15, 2014
Last Update Submitted That Met QC Criteria
July 14, 2014
Last Verified
July 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201404056MIPC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urticaria
-
Marcus MaurerCompletedNon-autoreactive Chronic Spontaneous Urticaria | Autoimmune Chronic Spontaneous Urticaria | Autoreactive, Non-autoimmune Chronic Spontaneous UrticariaGermany
-
J. Uriach and CompanyTerminated
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)CompletedUrticaria ChronicUnited States
-
United BioPharmaCompleted
-
Novartis PharmaceuticalsCompletedCHRONIC SPONTANEOUS URTICARIAFrance
-
University Hospital Inselspital, BerneNovartis; University of Bern; Adverse Drug Reactions, Advice and Consulting ADR-ACCompletedChronic Idiopathic Urticaria | Chronic Urticaria | Chronic Spontaneous UrticariaSwitzerland
-
University Hospital, LilleRecruitingSpontaneous Urticaria, ChronicFrance
-
United BioPharmaNot yet recruiting
-
United BioPharmaRecruiting
-
Second Xiangya Hospital of Central South UniversityNot yet recruitingChronic Spontaneous UrticariaChina
Clinical Trials on omalizumab
-
Massachusetts General HospitalGenentech, Inc.CompletedNasal Polyps | Chronic RhinosinusitisUnited States
-
Medical University of SilesiaCentrum Medyczne Andrzej BożekNot yet recruitingAsthma, Allergic
-
Novartis PharmaceuticalsCompletedCHRONIC SPONTANEOUS URTICARIAFrance
-
NovartisGenentech, Inc.; TanoxCompletedAsthmaUnited States, Argentina, Germany
-
Bernstein Clinical Research CenterWithdrawn
-
The University Clinic of Pulmonary and Allergic...UnknownAllergy | Immunotherapy | Omalizumab | Bee VenomSlovenia
-
Stanford UniversityCompletedAtopic DermatitisUnited States
-
Boston Children's HospitalStanford UniversityCompleted
-
IRCCS Policlinico S. MatteoCompletedInterstitial Cystitis | Painful Bladder SyndromeItaly